drugset / Trial / NCT05390710

PhI to Solid Tumors and PhII to Locally Advanced or mTNBC

NCT05390710

Phase 1 Completed 21 enrolled Laekna Limited
NaSingle-groupOpen-labelTreatment

Summary

PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D

Timeline

Start
2021-06-12
Primary completion
2023-12-11
Completion
2023-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Afuresertib Small molecule 125 mg
Subject LAE005 Unknown 1200 mg Intravenous
Subject Paclitaxel Small molecule 125 unknown